查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542919

全球雷射间接检眼镜市场 - 2024-2031

Global Laser Indirect Ophthalmoscope Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年，全球雷射间接检眼镜市场达到1.1529亿美元，预计2031年将达到1.6049亿美元，2024-2031年预测期间复合年增长率为4.3%。

雷射间接检眼镜会产生令人眼花撩乱的曝光和短暂的残像，但没有证据表明它们在常规临床使用中会导致光化学或热视网膜损伤。集中在单一视网膜区域的 15 分钟曝光可能会对麻醉的恒河猴造成局部光毒性损伤。儘管如此，在失明或需要摘除眼睛的人类志愿者中，仍无法检测到立即或长期的视网膜异常。

市场动态：

驱动程式和限制

雷射间接检眼镜进步的兴起

雷射间接检眼镜的技术进步，例如影像品质的提升、便携性和易用性，也促进了市场的成长。这些进步使这些设备对医疗保健提供者来说更容易使用和更具吸引力。数位成像和扩增实境等技术正在增强雷射间接检眼镜的功能，从而可以更好地可视化和诊断眼睛状况。

例如，Norlase 推出了 LION，这是一种新型雷射间接检眼镜 (LIO)，它结合了绿色雷射光凝器和 Keeler 间接检眼镜。这款电池供电的 LIO 不需要光纤繫绳，并使用先进的无线介面和语音控制参数。这使得眼科医生几乎可以在任何地方体验不受束缚、轻盈、便携式的雷射治疗解决方案。

监管挑战

雷射间接检眼镜在市场上面临许多监管挑战。其中包括获得 FDA 对新型号​​的许可、满足监管机构制定的安全和性能标准、遵守标籤和文件要求、适应各国不同的监管框架，以及随着更先进的型号的推出而管理日益严格的监管审查。这些挑战增加了开发过程的时间和成本，并使雷射间接检眼镜製造商的全球商业化工作变得复杂。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 雷射间接检眼镜进步的兴起
      • 眼部疾病盛行率上升
    • 限制
      • 监管挑战
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 专利分析
  • 大环境分析
  • SWOT分析
  • DMI 意见

第 6 章：按雷射类型

  • 光凝雷射
  • 光破坏雷射
  • 光烧蚀雷射

第 7 章：按治疗应用

  • 糖尿病视网膜病变
  • 白内障
  • 角膜混浊
  • 青光眼
  • 小儿视网膜修復
  • 晶格退化

第 8 章：最终用户

  • 医院
  • 眼科诊所
  • 门诊手术中心 (ASC)
  • 其他的

第 9 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Iridex Corporation
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Meridian AG
  • Lumenis
  • Ellex Medical Lasers
  • Carl Zeiss Meditec AG
  • Nidek Co. Ltd.
  • Ziemer Ophthalmic Systems AG
  • Heine Optotechnik GmbH
  • Keeler Ltd
  • Topcon Medical Laser Systems Inc (*LIST NOT EXHAUSTIVE)

第 12 章：附录

简介目录
Product Code: MD1252

Report Overview

The Global Laser Indirect Ophthalmoscope Market reached US$ 115.29 million in 2023 and is expected to reach US$ 160.49 million by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031.

Laser Indirect Ophthalmoscopes produce dazzling exposures and transient afterimages, but there is no evidence that they cause photochemical or thermal retinal injury in routine clinical use. A 15-minute exposure focused on a single retinal area can cause localized phototoxic injury in an anesthetized rhesus monkey. Still, no immediate or long-term retinal abnormalities could be detected in human volunteers with blind eyes or those requiring enucleation.

Market Dynamics: Drivers & Restraints

Rise of advancements in laser indirect ophthalmoscope

Technological advancements in laser indirect ophthalmoscopes, such as improved image quality, portability, and ease of use, are also contributing to the market's growth. These advancements make the devices more accessible and attractive to healthcare providers. Technologies like digital imaging and augmented reality are enhancing the capabilities of laser indirect ophthalmoscopes, allowing for better visualization and diagnosis of eye conditions.

For instance, Norlase has introduced the LION, a new laser indirect ophthalmoscope (LIO) that combines a green laser photocoagulator with a Keeler indirect ophthalmoscope. This battery-powered LIO requires no fiber tether and uses an advanced wireless interface with voice control of parameters. This allows ophthalmologists to experience an untethered, lightweight, and portable laser treatment solution virtually anywhere.

Regulatory challenges

The laser indirect ophthalmoscope faces numerous regulatory challenges in the market. These include obtaining FDA clearance for new models, meeting safety and performance standards set by regulatory bodies, adhering to labeling and documentation requirements, navigating differing regulatory frameworks across countries, and managing increased regulatory scrutiny as more advanced models are introduced. These challenges add time and costs to the development process and complicate global commercialization efforts for laser indirect ophthalmoscope makers.

Segment Analysis

The global laser indirect ophthalmoscope market is segmented based on laser type, therapeutic application, end-user, and region.

The photocoagulation laser from the laser type segment accounted for approximately 42.3% of the laser indirect ophthalmoscope market share

The photocoagulating laser from the laser type segment accounted for approximately 42.3%. Photocoagulation lasers, like argon and diode lasers, are widely used to treat retinal conditions like diabetic retinopathy and retinal vein occlusion by sealing blood vessels and reducing vision loss risk. This segment is expected to dominate due to increasing retinal disease incidence and photocoagulation therapy effectiveness.

For instance, in May 2023, Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, announced it had received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, investment by key players, advanced healthcare infrastructure, high adoption of advanced medical technologies, and increasing healthcare expenditure. However, rapid economic development, growing healthcare investments,

For instance, in May 2023, Norlase, a leading laser technology company, secured its largest investment round to date, raising $11 million. The funding will enable Norlase to accelerate the production of its ECHO pattern laser, which has received FDA clearance and CE Mark. The investment will also advance Norlase's laser treatment solution portfolio. West Hill Capital led the round.

Competitive Landscape

The major global players in the market include Iridex Corporation, Meridian AG, Lumenis, Ellex Medical Lasers, Carl Zeiss Meditec AG, Nidek Co. Ltd., Ziemer Ophthalmic Systems AG, Heine Optotechnik GmbH, Keeler Ltd, Topcon Medical Laser Systems Inc among others.

Key Developments

In January 2021, Norlase announced that it had been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase's groundbreaking compact laser technology into one device. With LION's untethered and portable design, physicians can move freely between treatment rooms - conveniently treating patients anywhere, anytime.

Why Purchase the Report?

To visualize the global laser indirect ophthalmoscope market segmentation based on laser type, therapeutic application, end user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

excel data sheet with numerous data points of the laser indirect ophthalmoscope market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global laser indirect ophthalmoscope market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Laser Type
  • 3.2. Snippet by Therapeutic Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise of advancements in laser indirect ophthalmoscope
      • 4.1.1.2. Rise in the prevalence of eye disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Laser Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 6.1.2. Market Attractiveness Index, By Laser Type
  • 6.2. Photocoagulation laser *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Photo disrupting laser
  • 6.4. Photo ablating laser

7. By Therapeutic Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 7.1.2. Market Attractiveness Index, By Therapeutic Application
  • 7.2. Diabetic retinopathy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cataract
  • 7.4. Corneal opacities
  • 7.5. Glaucoma
  • 7.6. Pediatric retinal repairs
  • 7.7. Lattice degeneration

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ophthalmic Clinics
  • 8.4. Ambulatory Surgery Centers (ASCs)
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Laser Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Iridex Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Meridian AG
  • 11.3. Lumenis
  • 11.4. Ellex Medical Lasers
  • 11.5. Carl Zeiss Meditec AG
  • 11.6. Nidek Co. Ltd.
  • 11.7. Ziemer Ophthalmic Systems AG
  • 11.8. Heine Optotechnik GmbH
  • 11.9. Keeler Ltd
  • 11.10. Topcon Medical Laser Systems Inc (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us